





Early-Career Training on Air Pollution and Health, August 12-14, 2024 | ICIMOD, Kathmandu, Nepal

# Introduction to Health Impact Assessment of air pollution

**Michal Krzyzanowski**Visiting Professor, Imperial College London



# This presentation

- Policy questions that health risk assessment (HRA) of AP answers;
- Measures of risk in population (RR, PAF, number of attributed cases, YLL, DALY);
- Main elements of risk assessment
- Uncertainties and limitations of HRA
- Examples of HRA use in policy making

# Estimation of health effects of exposure to air pollution in a population: Modes of Health Risk Assessment (HRA)

#### Burden

- What is the size of the problem currently?
- How much inflated are current mortality rates?
- How much potential life years are we losing?

#### **Impact**

- If we apply policy X, what will be the (expected) burden change?
- What will be the pattern of mortality rate change?
- What will be the pattern of changes in total life years?

## Model of risk reduction

I(Ex) / I(NEx) = RR (relative risk in Exposed vs. Not-exposed)

Incidence = number of cases / number of people at risk Incidence I(Ex) I(NEx) Not-exposed **Exposed Exposure** Counterfactual (cut-off) concentration

#### Measures of risk: Attributable risk

**Population Attributable Risk (PAR):** difference between the incidence of a disease in population with "real world" exposure and (often hypothetical) population not exposed; incidence attributable to the exposure.

$$PAR = I_{exposed} - I_{not \, exposed}$$


Population Attributable Fraction (PAF): fraction of the cases attributable to the exposure

$$PAF = (I_{exposed} - I_{not \, exposed}) / I_{exposed} = \frac{RR - 1}{RR}$$

$$PAR = PAF * I_{exposed}$$


Number of attributable cases = PAR \* NEx: number of people in exposed population

## Survival curves – effects of health levels in a population



YL = years of life

## Survival curves – effects of health levels in a population




Burden of disease: gap between a population's health status and that of a normative reference population

HIA intro

Integrated indicator of burden of disease: Disability-Adjusted Life Year (DALY)

- DALY is based on **years of life lost** from premature death and **years of life lived in disability** (less than full health);
- DALY single measure to quantify the burden of disease, injuries and risk factors;
- Introduced by Murray & Lopez in World Development Report 1993 prepared by WHO & HSPH for the World Bank;
- Several modifications of the methodology since 1993;
- DALYs for all WHO MS produced periodically by WHO based on databases and information provided by the MS.



WHO methods and data sources for global burden of disease estimates 2000 – 2019; WHO/DDI/DNA/GHE/2020.3 <a href="https://www.who.int/data/global-health-estimates">https://www.who.int/data/global-health-estimates</a>

# Disability weights (examples for selected diseases)

For GBD2019 and WHO GHE 2019: based on large population surveys and available for 234 health states.

Health state	Disability weight
Cancer	
Cancer: diagnosis and primary therapy	0.288
Cancer: metastatic	0.451
Cardiovascular diseases	
Acute myocardial infarction: days 1-2	0.432
Acute myocardial infarction: days 3-28	0.074
Stroke: long-term consequences, moderate	0.070
Stroke: long-term consequences, moderate plus cognition problems	0.316
Stroke: long-term consequences, severe	0.552
Stroke: long-term consequences, severe plus cognition problems	0.588
Chronic respiratory diseases	
Asthma: controlled	0.015
Asthma: partially controlled	0.036
Asthma: uncontrolled	0.133
COPD and other chronic respiratory problems, mild	0.019
COPD and other chronic respiratory problems, moderate	0.225
COPD and other chronic respiratory problemടോടvere	0.408 W

# This presentation

- Policy questions that health risk assessment (HRA) of AP answers;
- Measures of risk in population (RR, PAF, number of attributed cases, YLL, DALY);
- Main elements of risk assessment
- Uncertainties and limitations of HRA
- Examples of HRA use in policy making

# HRA: Selection of pollutant – outcome pair: criteria to consider

- Strength of evidence on causality of the association
- Public health interpretation of the health outcome (direct vs. indirect measures of health)
- Availability of studies providing concentration-response functions (CRFs)
- Availability of data on exposure
- Availability of data on the health outcome frequency in the assessed population

# Causality determinations on the long- and short-term effects of air pollutants for different disease categories

Catagory	PM <sub>2.5</sub> (E	PA 2019)	NO <sub>2</sub> (	EPA 2016)	Ozone (EPA 2020)	
Category	Long-term	Short-term	Long-term	Short-term	Long-term	Short-teri
Reproductive and						
Developmental	Suggestive	Suggestive	Suggestive	Suggestive	Suggestive	
effects						
Respiratory effects	Likely	Likely	Likely	Causal	Likely	Causal
Cardiovascular diseases	Causal	Causal	Suggestive	Suggestive	Suggestive	Suggestive
Metabolic effects	Suggestive	Suggestive	Suggestive	Suggestive	Suggestive	Likely
Neurological effects Likely Suggestive				Suggestive	Suggestive	
Cancer (lung cancer) Likely (a)		Suggestive		Inadequate		
Mortality	Causal	Causal	Suggestive	Suggestive	Suggestive	Inadequate


<sup>(</sup>a) IARC 2013: PM<sub>2.5</sub> and PM<sub>10</sub> exposure is carcinogenic to humans (Group 1)

## Input information needed for HRA

- Current exposure level (or exposure distribution in the population) (C)
- Reference exposure level (counterfactual) (C<sub>0</sub>)
- Concentration-response function (CRF, RR)

Background incidence of health outcome (I)

Size of target population (N)



## Selection of exposure data for HRA

#### Pollutants:

- Particulate Matter ≤ 2.5µm (PM2.5) (not available, can be estimated from PM10 data using PM2.5/PM10 ratio from local observations or literature)
- Particulate Matter ≤ 10µm (PM10);
- Ozone (O3);
- Nitrogen Dioxide (NO2);
- Black Carbon (BC);

#### Selection of monitoring stations providing data:

- Data from continuous monitoring (with at least 18 h of measurements per day) for more than 75% of the days in a year
- Located in residential area of the city and far from industrial emission sources;
- Data from "traffic" stations (located within 50 m from roads with intensive traffic) should not be used unless they are also located in densely populated area and could be considered characteristic for residents' exposure.
- If data available from more than 1 station in a population take all data.

# Location of air quality monitors - examples



# Surrounding of the monitoring station

In front of the wall



Behind the wall




# DIMAQ model estimates for PM2.5


Annual mean, 2014

Uncertainty in annual mean, 2014


Shaddick et al, J Roy Stat Soc C 2018



#### Annual mean PM2.5 air pollution in London, based on measurements made in 2016



# Population-weighted mean concentration



C1 - concentration in location 1 (31 µg/m³) C2 - concentration in location 2 (22 µg/m³)

n1 – population in district 1 (120 000) n2 – population in district 2 (60 000)

N=n1+n2 – total population of the city (180 000)

C – population-weighted city mean concentration:

C = (C1\*n1 + C2\*n2)/N 
$$C = \sum_{i=0}^{m} C_i * n_i / N$$


$$C = (31*120000 + 22*60000)/180000 = 28 \mu g/m^3$$


(mean of C1 and C2 =  $26.5 \mu g/m^3$ )

**Population-Weighted Concentration** 

**Burden On Your Health** 

https://www.stateofglobalair.org/data-cities/#/air/plot






## Input information needed for HRA

- Current exposure level (or exposure distribution in the population) (C)
- Reference exposure level (counterfactual) (C<sub>0</sub>)
- Concentration-response function (CRF, RR)

Background incidence of health outcome (I)

Size of target population (N)



## Reference exposure level (counterfactual)

#### Health burden analysis:

- The lowest exposure level observed
- MGBD study: πισοιο...

  PM2.5: 2.416a9μg/m³)

   Exposure level with RR>1ed and reported in each HRA! • MGBD study: Theoretical Minimum Risk Exposure Level (for

#### Impact assessment:


 Exposure level expected (assumed) after planned intervention or policy scenario

# Input information needed for HRA

- Current exposure level (or exposure distribution in the population) (C)
- Reference exposure level (counterfactual) (C<sub>0</sub>)
- Concentration-response function (CRF, RR)


Background incidence of health outcome (I)


Size of target population (N)




# CRFs for all-cause mortality based on selected studies

Cohort of 60 925 433 US adults, age 65+, followed 2000-2012; RR for all-cause mortality (Di et al, NEJM 2017)






# Long-term exposure to PM2.5 and natural-cause mortality – systematic review and meta-analysis supporting WHO 2021 update



# Extrapolation of CRFs to high exposure ranges in GBD study



# Selection of systematic reviews on the effects long term exposure to PM2.5 on morbidity in EMAPEC project (PROSPERO: CRD42023397145)

SRS   SRS   SRS   Good   Goulety   Good   Goulety   Good   Goulety   Good   Goulety   Good   Good										
Asthma in children 11 9 6 2  Asthma onset in adults 0  ALRI in children 3 2 2 0  ALRI in adults 0  COPD 7 2 2 1  IHD events 11 7 6 1  Stroke 12 8 6 2  Heart failure 2 1 1 0  Atrial fibrillation 5 4 4 1  Hypertension 12 8 7 2  Diabetes 9 8 3 2  Dementia 7 6 6 2  Parkinson disease 8 6 3 1  Autism Spectrum Disorder 8 7 4 4  Lung cancer 11 9 3 2									_	
Asthma onset in adults       0         ALRI in children       3       2       2       0         ALRI in adults       0		PM2.5, long term		found	included	evaluated	Quality			
ALRI in children       3       2       2       0         ALRI in adults       0	Α	Asthma in children			11	9	6	2		
ALRI in adults       0         COPD       7       2       2       1         IHD events       11       7       6       1         Stroke       12       8       6       2         Heart failure       2       1       1       0         Atrial fibrillation       5       4       4       1         Hypertension       12       8       7       2         Diabetes       9       8       3       2         Dementia       7       6       6       2         Parkinson disease       8       6       3       1         Autism Spectrum Disorder       8       7       4       4         Lung cancer       11       9       3       2	Α	sthma on	set in	adults		0				
COPD       7       2       2       1         IHD events       11       7       6       1         Stroke       12       8       6       2         Heart failure       2       1       1       0         Atrial fibrillation       5       4       4       1         Hypertension       12       8       7       2         Diabetes       9       8       3       2         Dementia       7       6       6       2         Parkinson disease       8       6       3       1         Autism Spectrum Disorder       8       7       4       4         Lung cancer       11       9       3       2	Α	LRI in chil	dren			3	2	2	0	
IHD events       11       7       6       1         Stroke       12       8       6       2         Heart failure       2       1       1       0         Atrial fibrillation       5       4       4       1         Hypertension       12       8       7       2         Diabetes       9       8       3       2         Dementia       7       6       6       2         Parkinson disease       8       6       3       1         Autism Spectrum Disorder       8       7       4       4         Lung cancer       11       9       3       2	Α	LRI in adu	lts			0				
Stroke       12       8       6       2         Heart failure       2       1       1       0         Atrial fibrillation       5       4       4       1         Hypertension       12       8       7       2         Diabetes       9       8       3       2         Dementia       7       6       6       2         Parkinson disease       8       6       3       1         Autism Spectrum Disorder       8       7       4       4         Lung cancer       11       9       3       2	С	OPD				7	2	2	1	
Heart failure       2       1       1       0         Atrial fibrillation       5       4       4       1         Hypertension       12       8       7       2         Diabetes       9       8       3       2         Dementia       7       6       6       2         Parkinson disease       8       6       3       1         Autism Spectrum Disorder       8       7       4       4         Lung cancer       11       9       3       2	IH	HD events				11	7	6	1	
Atrial fibrillation       5       4       4       1         Hypertension       12       8       7       2         Diabetes       9       8       3       2         Dementia       7       6       6       2         Parkinson disease       8       6       3       1         Autism Spectrum Disorder       8       7       4       4         Lung cancer       11       9       3       2	S	troke				12	8	6	2	
Hypertension       12       8       7       2         Diabetes       9       8       3       2         Dementia       7       6       6       2         Parkinson disease       8       6       3       1         Autism Spectrum Disorder       8       7       4       4         Lung cancer       11       9       3       2	Н	leart failur	e			2	1	1	0	
Diabetes       9       8       3       2         Dementia       7       6       6       2         Parkinson disease       8       6       3       1         Autism Spectrum Disorder       8       7       4       4         Lung cancer       11       9       3       2	Α	trial fibrill	ation			5	4	4	1	
Dementia       7       6       2         Parkinson disease       8       6       3       1         Autism Spectrum Disorder       8       7       4       4         Lung cancer       11       9       3       2	Н	lypertensi	on			12	8	7	2	
Parkinson disease       8       6       3       1         Autism Spectrum Disorder       8       7       4       4         Lung cancer       11       9       3       2	D	iabetes				9	8	3	2	
Autism Spectrum Disorder 8 7 4 4 Lung cancer 11 9 3 2	D	Dementia			7	6	6	2		
Lung cancer 11 9 3 2	Р	Parkinson disease			8	6	3	1		
	Α	Autism Spectrum Disorder			8	7	4	4		
	L	ung cance	r			11	HIA intro	3	2	

#### "Good quality" SR:

- all critical criteria met,
- not more than 4 other criteria missed

Forastiere et al., Env Epi 2024

#### Relative risk estimates for incidence of diseases from selected systematic reviews recommended for health risk assessment of PM<sub>2.5</sub> (WHO EMAPEC project)

Outcome (incidence)	ICD10 codes	Age (years)	List	RR (95%CI) per 10 μg/m³	Mean exposure range (μg/m³)	SR reference
		(7)		1-07		
Asthma in	J45	0 - 18	Α	1.34 (1.10; 1.63)	5 - 38	Khreis et al. (2017)
children						
COPD	J41 — J44	30+	Α	1.18 (1.13; 1.23)	5 - 26	Park et al. (2021)
IHD events	121-122	30+	Α	1.13 (1.05; 1.22)†	5 - 65	Zhu et al. (2021)
Stroke	160 – 164	30+	Α	1.16 (1.12; 1.20)†	5 - 36	Yuan et al. (2019)
Hypertension	l10 - l11	30+	Α	1.17 (1.05; 1.30)†	5 - 77	Qin et al. (2021)
Diabetes	E11 – E14	30+	B+	1.10 (1.03; 1.18)†	5 - 79	Yang BY et al. (2020)
Dementia	F00-F03, G30	60+	Α	1.46 (1.12; 1.77)†	5 <b>–</b> 25§	Cheng et al. (2022)
Autism SD	F84.0, F84.1,	2 - 12	B+	1.66 (1.23; 2.25)†	5 <b>–</b> 30§	Lin LZ et al. (2022)
	F84.5, F84.8,					
	F84.9					
Lung cancer	C34	30+	Α	1.16 (1.10; 1.23)	5 - 44	Yu et al. (2021)

<sup>†</sup> Relative risk estimates from revised meta-analysis


<sup>§</sup> Restrict applicability of the CRFs of these conditions to exposure differences not larger than 10 μg/m³ within the indicated concentration ranges HIA intro

# Input information needed for HRA

- Current exposure level (or exposure distribution in the population) (C)
- Reference exposure level (counterfactual) (C<sub>0</sub>)
- Concentration-response function (CRF, RR)

Background incidence of health outcome (I)

Size of target population (N)



# Example: City X

- Current annual mean PM2.5 exposure level in City X C= 51 μg/m<sup>3</sup>
- The plan is to reduce it to  $C_0 = WHO IT1 = 35 \mu g/m^3$  (i.e. by 16  $\mu g/m^3$ )
- CRF for all-cause mortality based on Chen & Hoek 2020, RR= 1.08 per 10  $\mu g/m^3$  , i.e. 1.131 per 16  $\mu g/m^3$

PAF = (1.131 - 1)/1.131 = 0.116 (11.6% of total mortality can be attributed to the exposure > 35  $\mu$ g/m³ in City X)

• What if  $C_0 = 25 \,\mu\text{g/m}^3$  (WHO IT2)? (RR per 26  $\mu\text{g/m}^3 = 1.222$ )


 $PAF = (1.222 - 1)/1.222 = 0.182 (18.2\% \text{ of total mortality can be attributed to the exposure} > 25 \,\mu\text{g/m}^3 \text{ in City X})$ 

# Input information needed for HRA

- Current exposure level (or exposure distribution in the population) (C)
- Reference exposure level (counterfactual) (C<sub>0</sub>)
- Concentration-response function (CRF, RR)

Background incidence of health outcome (I)

Size of target population (N)



# Data on the health outcome frequency in the HRA target population

#### Optimal:

- official health statistics for the target population (city, province, ...)
- For the most recent year (or mean of several years)
- For the age group for which CRF applies (e.g. 30+)



- If the optimal data not available:
  - Take (incidence) data for the larger population, containing the target area
  - Make (information based) assumptions for estimating the data for the target group
  - Use the data (or estimates) for similar areas (countries?) not containing the target population from international sources

#### WHO MORTALITY DATABASE

Interactive platform visualizing mortality data

https://platform.who.int/mortality/themes/theme-details/MDB/all-causes

Cause of death explorer **∨** Country or area profile About > Portal home Resources

#### All causes


#### Reset to default Causes of death explorer All causes 公 N • Communicable, maternal, perinatal and nutritional conditions Noncommunicable diseases Deaths by sex and age group for a selected country or area and year Injuries III-defined diseases Age groups\* Country or area\* $AII \times$ Sri Lanka X × Search... Search... Sex\* Year $AII \times$ 2019 × Search... **Related data**




Death rate per 100 000 population

686.5


#### Mortality rates in South Asia countries – GBD project estimates



#### Mortality rates in India states – GBD project estimates



# Number of IHD deaths, age 50-69 years, in India states – GBD project estimates



# Example: City X, cont.

- Current annual mean PM2.5 exposure level in City X C= 51 μg/m<sup>3</sup>
- The plan is to reduce it to  $C_0 = WHO IT1 = 35 \mu g/m^3$  (i.e. by 16  $\mu g/m^3$ )
- CRF for all-cause mortality based on Chen & Hoek 2020, RR= 1.08 per 10 µg/m³, i.e. 1.131 per 16 µg/m³

PAF = (1.131 - 1)/1.131 = 0.116 (11.6% of total mortality can be attributed to the exposure > 35 µg/m<sup>3</sup> in City X)

• All-cause mortality in age 30+ is I=1400 per 100 000 pop.

Population attributable risk PAR = I\*PAF= 1400 \* 0.116= 162.4 per 100 000 pop. (mortality attributable to the exposure > 35  $\mu$ g/m<sup>3</sup>)

Total population: 1.4 million, 55% in age 30+, NEx=1 400 000\*0.55= 770 000 in age 30+
 Number of attributable cases = NEx \* PAR= (770 000/ 100 000) \* 162.4 = 1250 deaths / year attributable to exposure > 35 μg/m³

# GBD estimates of ambient particulate matter attributable burden of disease in 2021 (both sexes)

Counterfactual PM2.5  $C_0$  = TRMEL 2.4-5.9  $\mu$ g/m<sup>3</sup>

Country	PM attributable:						
	Number of deaths	Mortality rate per 100 000	DALYs	DALYs per 100 000			
Bangladesh	41900	25.4	1188000	722			
India	837500	67.0	27410000	1940			
Nepal	12700	40.7	363300	1170			
Pakistan	103000	43.7	4399000	1870			
Sri Lanka	11400	51.1	279300	1250			

https://www.stateofglobalair.org/

### This presentation

- Policy questions that health risk assessment (HRA) of AP answers;
- Measures of risk in population (RR, PAF, number of attributed cases, YLL, DALY);
- Main elements of risk assessment
- Uncertainties and limitations of HRA
- Examples of HRA use in policy making



Evaluation Name:	City X					€	
Health Endpoint							
Health Endpoint:	Mortality, all (n	Mortality, all (natural) causes (adults age 30+ years)					
Incidence (per 100 000 Population a	it risk per year): 🜹	<b>②</b>	1400				
Pop. at risk (55%):		# 🥝	770000				
Calculation Parameters							
Calculation Method:	log-linear				<b>—</b>		
Relative Risk:	<b>②</b>	1.08 L	ower:	1.06 Upper:	<b>②</b>	1.09	
Cut-off Value X0 (see formula)	<b>②</b>	35					
Mean Concentration X: 숙	51						
Advanced						*	
				Calculate			
Results (last calculation 2024-08-05 13	3:58:18)						
			Central	Lower	Uppe	r 🖫	

1,249

162.20

960

124.62

Estimated number of Attributable Cases

Estimated number of Attributable Cases per 100,000 Population at Risk


1,388


180.32

HEALTH IMPACT
Burden On Your Health

**Population-Weighted Concentration** 

https://www.stateofglobalair.org/data-cities/#/health/plot





# Sources of uncertainty in HRA

- Concentration response function:
  - Shape and range of applicability
  - Statistical uncertainty
- Level of exposure
  - Current (C)
  - Expected / counterfactual (C<sub>0</sub>)
- Baseline incidence and population data

**Good practice**: analysis of sensitivity to various versions of input data and assumptions

### This presentation

- Policy questions that health risk assessment (HRA) of AP answers;
- Measures of risk in population (RR, PAF, number of attributed cases, YLL, DALY);
- Main elements of risk assessment
- Uncertainties and limitations of HRA
- Examples of HRA use in policy making

# Air Quality management: a cyclical process




https://www.who.int/europe/publications/i/item/WHO-EURO-2023-6898-46664-67857



# Use of GBD results to inform policy

Air pollution
Both sexes, All ages, 2021, Deaths per 100,000



Int. J. Environment and Health, Vol. 10, Nos. 3/4, 2021

213

#### Air pollution exposure and health impacts in the Kathmandu valley

#### Srijan Lal Shrestha\*

Central Department of Statistics, Tribhuvan University, Kirtipur, Kathmandu, Nepal Email: srijan\_shrestha@yahoo.com Email: srijan.shrestha@cds.tu.edu.np \*Corresponding author

#### Pierpaolo Mudu

Environment, Climate Change and Health, World Health Organization (WHO), 20 Avenue Appia, CH-1211, Geneva, Switzerland Email: mudup@who.int

#### Peter DeCarlo


Department of Environmental Health and Engineering, Johns Hopkins University, 2400 North Charles Street, Baltimore, MD 21218-2608, USA Email: pdecarl1@jhu.edu

RR=1.06 (1.04, 1.08) from Hoek et al 2012)

**Table 5B** Mortality (Aged 30 and above) attributable and avoidable fractions and burdens from  $PM_{2.5}$  ambient air pollution in Kathmandu valley using WHO HRAPIE estimate

	-	Attributable		-	Avoidable		
Period	Measure	Central	Lower	Upper	Central	Lower	Upper
Baseline	Attributable fraction	0.2015	0.1364	0.2579	_	_	_
(2017– 2020)	Attributable cases	1979	1340	2533	_	_	_
	Attributable cases per 100, 000 population at risk	128.53	87.05	164.51	_	-	-
BAU (35% Reduction)	Attributable/Avoidable fraction	0.1269	0.0847	0.1646	0.0746	0.05175	0.09322
	Attributable/Avoidable cases	1679	1121	2179	300	220	355
	Attributable/Avoidable cases per 100, 000 population at risk	73.98	49.37	95.98	54.55	37.68	68.53
Progressive (60%	Attributable/Avoidable fraction	0.0694	0.0458	0.0910	0.1320	0.0906	0.1669
	Attributable/Avoidable cases	919	606	1204	1061	734	1330
	Attributable/Avoidable cases per 100, 000 population at risk	40.47	26.72	53.03	88.06	60.33	111.48

# Impact assessment for revision of EU AQ Directive (2022)




# Study to support the impact assessment for a revision of the EU Ambient Air Quality Directives

Specific Contract under Framework Contract ENV/F1/ FRA/2019/0001

#### **Final Report**

https://op.europa.eu/en/publication-detail/-/publication/a05c2e91-54db-11ed-92ed-01aa75ed71a1/language-en

Impact of the scenarios on the premature mortality for PM<sub>2.5</sub> Relative difference between the scenario and the baseline.



# Summary

#### HRA provides:

- Quantitative estimates of the burden of air pollution on population health
- Estimates of the impacts of selected policies affecting air pollution on health
- Basis for economic assessment of air pollution health burden and its changes due to policies (not discussed here)
- Essential arguments supporting clean air policy

#### • HRA requires:

- Relevant data on population exposure and its expected changes due to policy under study
- Reliable concentration-response functions (from epidemiology)
- Data on relevant health indicators for the target population
- Expertise in HRA implementation